PDF icon PDF herunterladen
Open Access
CC BY 4.0 · Chinese medicine and natural products 2025; 05(02): e115-e123
DOI: 10.1055/s-0045-1809685
Original Article

Study on the Mechanism of Mahuang Xixin Fuzi Decoction in Treating AR and Prediction of Its Q-Markers Based on Network Pharmacology and Molecular Docking

Lingli Cao
1   Department of Pharmacy, Zhengzhou Health Vocational College, Zhengzhou, Henan, China
,
Xiaomin Chen
1   Department of Pharmacy, Zhengzhou Health Vocational College, Zhengzhou, Henan, China
,
Yun Guo
1   Department of Pharmacy, Zhengzhou Health Vocational College, Zhengzhou, Henan, China
,
Yinman Feng
1   Department of Pharmacy, Zhengzhou Health Vocational College, Zhengzhou, Henan, China
› Institutsangaben
Funding This work was supported by Henan Province 2024 Science and Technology Development Plan (242102310577).
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

Objective

This study aimed to investigate the potential mechanism of Mahuang Xixin Fuzi Decoction in treating allergic rhinitis (AR) and predict its quality markers (Q-markers) using network pharmacology and molecular docking techniques.

Methods

The chemical components of the herbal constituents in Mahuang Xixin Fuzi Decoction were retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Active component-related targets were screened using the SwissTargetPrediction database, while AR-related targets were obtained from the GeneCards database. The intersection targets (potential therapeutic targets of the Mahuang Xixin Fuzi Decoction for AR) were identified via the Venn 2.1.0 platform, and a Venn diagram was constructed. A “herb–active component–potential target” network was established using Cytoscape 3.10.0, and core components were screened via topological analysis. Protein–protein interaction (PPI) network of the intersection targets was built using the String database, followed by topological analysis to identify core targets. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed on the core targets using the DAVID database. Molecular docking of core components and targets was conducted using AutoDock Tools 1.5.7.

Results

Twenty-seven active components were identified from TCMSP, with 506 corresponding targets predicted by SwissTargetPrediction. A total of 2,447 AR-related targets were retrieved from GeneCards, yielding 165 intersection targets. Network analysis revealed naringenin, genkwanin, deoxyandrographolide, karakoline, and karanjin as core components. PPI network analysis identified 32 core targets. GO enrichment analysis screened 834 functional items, including 618 biological processes, 72 cellular components, and 144 molecular functions. KEGG analysis identified 165 signaling pathways. Molecular docking confirmed stable binding between core components and key targets.

Conclusion

Multiple chemical components in Mahuang Xixin Fuzi Decoction may ameliorate AR by regulating diverse targets and biological processes. Naringenin, genkwanin, and deoxyandrographolide are proposed as potential Q-markers for this decoction in AR treatment.

Keywords

allergic rhinitis - Mahuang Xixin Fuzi Decoction - Q-markers - network pharmacology - molecular docking

CRediT Authorship Contribution Statement

Lingli Cao: Project administration, data curation, formal analysis, and writing -original draft. Xiaomin Chen: Writing-review and editing. Yun Guo: Writing-review and editing. Yinman Feng: Project administration and funding acquisition.




Publikationsverlauf

Eingereicht: 22. Januar 2025

Angenommen: 25. März 2025

Artikel online veröffentlicht:
27. Juni 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Kong Q, Cong LN. Efficacy of the Mahuang Fuzi Xixin decoction on bronchopneumoniain children. Clin J Chin Med 2019; 11 (34) 74-76
    Suche in Google Scholar
  • 2 Zhang XX, Lyu XD, Pang LJ. et al. Efficacy evaluation of Modified Mahuang Fuzi Xixin Decoction in the treatment of adult asthma. Liaoning Zhongyiyao Daxue Xuebao 2020; 22 (09) 126-131
    Suche in Google Scholar
  • 3 Wang TJ, Yu RZ, Liu YM. Brief analysis of Mahuang Fuzi Xixin Decoction in treating lung collateral disease. Zhonghua Zhongyiyao Xuekan 2023; 41 (10) 38-40
    Suche in Google Scholar
  • 4 Cui HQ. Effects of Modified Guizhi Decoction without Shaoyao but with Mahuang, Xixin and Fuzi Decoction on neurological function in patients with cerebral infarction. Henan Tradit Chin Med 2020; 40 (10) 1507-1510
    Suche in Google Scholar
  • 5 Cai Q, Qian L. Summary of clinical experience in treating sick sinus syndrome with Mahuang Fuzi Xixin Decoction. Gansu Med J 2019; 38 (11) 987-989
    Suche in Google Scholar
  • 6 Nie YX, Xie HB, Wang LX. et al. Experience of Xie Haibo in treating bradyarrhythmia with Mahuang Fuzi Xixin Decoction. Asia-Pacific Tradit Med 2023; 19 (04) 97-99
    Suche in Google Scholar
  • 7 Zhan CS. Clinical efficacy of modified Mahuang Fuzi Xixin Decoction in treating chronic arrhythmia. Linchuang Heli Yongyao Zazhi 2022; 15 (34) 38-41
    Suche in Google Scholar
  • 8 Zhang SJ, Wang XR, Li XY. et al. Empirical cases of Mahuang Fuzi Xixin Decoction in treating yang deficiency and cold coagulation disease. Chin J Ethnomed Ethnopharm 2023; 32 (21) 88-90
    Suche in Google Scholar
  • 9 Gao YG. Clinical observation of Lizhong Decoction combined with Mahuang Fuzi Xixin Decoction in the treatment of acute allergic rhinitis due to deficiency-cold. Chin Med Digest (Otorhinolaryngol) 2023; 38 (04) 53-55
    Suche in Google Scholar
  • 10 Xing YW, Zhang YX, Li Y. et al. Chen Shouqiang's clinical experience in treating allergic rhinitis with fusion acupuncture combined with Mahuang Xixin Fuzi Decoction. Guid J Tradit Chin Med Pharm 2024; 30 (03) 164-167
    Suche in Google Scholar
  • 11 Li L, Su K. Professor Chen Xue Zhong's experience in treating allergic diseases with Modified Mahuang Fuzi Xixin Decoction. Guangxi Zhongyiyao 2021; 44 (02) 42-44
    Suche in Google Scholar
  • 12 Liu SY, Wang SP. Effects of Mahuang Xixin Fuzi Decoction on INF-γ and IL-13 levels in rats with allergic rhinitis. Henan Tradit Chin Med 2017; 37 (08) 13
    Suche in Google Scholar
  • 13 Lu XP, Xu L, Meng LW, Wang LL, Niu J, Wang JJ. Divergent molecular evolution in glutathione S-transferase conferring malathion resistance in the oriental fruit fly, Bactrocera dorsalis (Hendel). Chemosphere 2020; 242: 125203
    CrossrefPubMedSuche in Google Scholar
  • 14 Jing SS, Zhang FY, Wang RZ. Research progress on the treatment of allergic rhinitis by traditional Chinese medicine through regulating mitochondrial quality control. Guid J Tradit Chin Med Pharm 2025; 31 (03) 155-162
    Suche in Google Scholar
  • 15 Li M, Li W, Xia YF. et al. Protective effect of compound glycyrrhizin on lung injury in mice with viral pneumonia via the PI3K/Akt/NF-κB Pathway. Zhongchengyao 2023; 45 (11) 3775-3779
    Suche in Google Scholar
  • 16 Gavino AC, Nahmod K, Bharadwaj U, Makedonas G, Tweardy DJ. STAT3 inhibition prevents lung inflammation, remodeling, and accumulation of Th2 and Th17 cells in a murine asthma model. Allergy 2016; 71 (12) 1684-1692
    CrossrefPubMedSuche in Google Scholar
  • 17 Wang J, Shen Y, Li C. et al. IL-37 attenuates allergic process via STAT6/STAT3 pathways in murine allergic rhinitis. Int Immunopharmacol 2019; 69: 27-33
    CrossrefPubMedSuche in Google Scholar
  • 18 Xiao X, Kang LP, Dai D. et al. Mechanism of Kai Xuan Jie Du Core Formula in improving skin lesions of psoriasis model mice by regulating PTGS2. Chin J Exp Tradit Med Formul 2025; 5: 1-19
    CrossrefSuche in Google Scholar
  • 19 Huang R, Yu J, Zhang B, Li X, Liu H, Wang Y. Emerging COX-2 inhibitors-based nanotherapeutics for cancer diagnosis and treatment. Biomaterials 2025; 315: 122954
    CrossrefPubMedSuche in Google Scholar
  • 20 Morotti M, Grimm AJ, Hope HC. et al. PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. Nature 2024; 629 (8011) 426-434
    CrossrefPubMedSuche in Google Scholar
  • 21 Liu XY. Network Pharmacology-based Approach for Investigating the Pharmacological Mechanism of Xanthii Fructus Active Ingredients in Treatment of Allergic. Qingdao: Qingdao University; 2023
    Suche in Google Scholar